Roberts Pharmaceutical

Roberts Pharmaceutical was a specialty pharmaceutical company that focused on the acquisition and development of niche therapeutic products and late-stage drug candidates. Based in New Jersey, the company established a significant presence in therapeutic areas such as oncology, gastroenterology, and respiratory health. Its business model centered on revitalizing under-marketed drugs and advancing clinical-stage assets toward commercialization. In 2000, the company was acquired by Shire Pharmaceuticals for approximately $1 billion. This acquisition provided Shire with a robust US sales infrastructure and several key products, including Agrylin and ProAmatine. The company's legacy continues through its products, which became core components of Shire's and later Takeda's portfolios.